白塞病
Behçet disease
定义 英文原文(暂无中文)
A rare, chronic, relapsing, multisystemic vasculitis characterized by mucocutaneous lesions, as well as articular, vascular, ocular and central nervous system manifestations.
基本事实
- 遗传方式
- 多基因/多因素
- 发病年龄
- 青少年期、成年期、儿童期
- 患病率
- 1-9 / 1 000 000(Spain)
相关基因 15
| 基因 | 名称 | 关联类型 |
|---|---|---|
| FAS | Fas cell surface death receptor | Major susceptibility factor in |
| HLA-B | major histocompatibility complex, class I, B | Major susceptibility factor in |
| IFNGR1 | interferon gamma receptor 1 | Major susceptibility factor in |
| IL10 | interleukin 10 | Major susceptibility factor in |
| IL23R | interleukin 23 receptor | Major susceptibility factor in |
| MEFV | MEFV innate immunity regulator, pyrin | Major susceptibility factor in |
| C4A | complement C4A (Chido/Rodgers blood group) | Major susceptibility factor in |
| IL12A | interleukin 12A | Major susceptibility factor in |
| UBAC2 | UBA domain containing 2 | Major susceptibility factor in |
| STAT4 | signal transducer and activator of transcription 4 | Major susceptibility factor in |
| TLR4 | toll like receptor 4 | Major susceptibility factor in |
| CCR1 | C-C motif chemokine receptor 1 | Major susceptibility factor in |
| KLRC4 | killer cell lectin like receptor C4 | Major susceptibility factor in |
| IL12A-AS1 | IL12A antisense RNA 1 | Major susceptibility factor in |
| ERAP1 | endoplasmic reticulum aminopeptidase 1 | Major susceptibility factor in |
临床表型 85
极常见 99–80%14
- 关节炎 HP:0001369
- 疲乏 HP:0012378
- 发热 HP:0001945
- 脑膜炎 HP:0001287
- 偏头痛 HP:0002076
- 肌痛 HP:0003326
- 恶心和呕吐 HP:0002017
- 口腔溃疡 HP:0000155
- 睾丸炎 HP:0100796
- 丘疹 HP:0200034
- 畏光 HP:0000613
- 复发性口疮性口炎 HP:0011107
- 皮下结节 HP:0001482
- 血管炎 HP:0002633
常见 79–30%21
- 腹痛 HP:0002027
- 皮肤的异常起疱 HP:0008066
- 痤疮 HP:0001061
- 关节疼痛 HP:0002829
- 意识模糊 HP:0001289
- C-反应蛋白水平升高 HP:0011227
- 红细胞沉降速度升高 HP:0003565
- 结节性红斑 HP:0012219
- 步态异常 HP:0001288
- 胃肠道出血 HP:0002239
- 生殖器溃疡 HP:0003249
- 头痛 HP:0002315
- 轻偏瘫 HP:0001269
- 免疫过敏 HP:0100326
- 炎症反应增强 HP:0012649
- 非肉芽肿性葡萄膜炎 HP:0007813
- 全葡萄膜炎 HP:0012121
- 针刺反应阳性 HP:0025532
- 脓疱 HP:0200039
- 浅表性血栓性静脉炎 HP:0002638
- 静脉血栓形成 HP:0004936
偶见 29–5%48
- AA淀粉样变 HP:4000041
- 心肌形态异常 HP:0001637
- 锥体束征 HP:0007256
- 厌食症 HP:0002039
- 主动脉瓣反流 HP:0001659
- 动脉血栓形成 HP:0004420
- 共济失调 HP:0001251
- 非典型行为 HP:0000708
- 缺血性坏死 HP:0010885
- 失明 HP:0000618
- 白内障 HP:0000518
- 脑缺血 HP:0002637
- 颅神经麻痹 HP:0006824
- 发育倒退 HP:0002376
- 心内膜炎 HP:0100584
- 附睾炎 HP:0000031
- 坏疽 HP:0100758
- 肾小球病 HP:0100820
- 咯血 HP:0002105
- 反射亢进 HP:0001347
- 颅内压增高 HP:0002516
- 传染性脑炎 HP:0002383
- 易激惹 HP:0000737
- 干燥性角结膜炎 HP:0001097
- 淋巴结肿大 HP:0002716
- 吸收不良 HP:0002024
- 记忆障碍 HP:0002354
- 二尖瓣反流 HP:0001653
- 心肌梗死 HP:0001658
- 心肌炎 HP:0012819
- 肌炎 HP:0100614
- 非感染性脑膜炎 HP:0033430
- 视神经炎 HP:0100653
- 胰腺炎 HP:0001733
- 感觉异常 HP:0003401
- 心包炎 HP:0001701
- 胸腔积液 HP:0002202
- 胸膜炎 HP:0002102
- 肺栓塞 HP:0002204
- 肺浸润 HP:0002113
- 阵发性发热 HP:0001954
- 肾功能不全 HP:0000083
- 视网膜病变 HP:0000488
- 球后视神经炎 HP:0100654
- 癫痫发作 HP:0001250
- 脾肿大 HP:0001744
- 眩晕 HP:0002321
- 体重减轻 HP:0001824
罕见 <4–1%2
- 腹泻 HP:0002014
- 肾小球肾炎 HP:0000099
近两年的全球研究 597L2
2024/08 起在 Europe PMC 检索所得,按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务,尚未引入。
- 2026-08荟萃分析系统综述INCIDENCE AND PREVALENCE OF NONINFECTIOUS UVEITIS: A Systematic Review and Meta-Analysis
- 2026-07Pegylated interferon-α-2a in severe Adamantiades-Behçet disease: A series of seven cases
- 2026-07病例报告Extra-Anatomical Aortic Bypass for Infected Aortic Arch Stent Graft: A Case Series
- 2026-07The Association Between Vitiligo and Uveitis: A Large Population-Based Study
- 2026-07病例报告Exuberant Dermatitis Herpetiformis With Oral Involvement Mimicking Behçet Disease and Disseminated Herpetic Infection: The Crucial Role of Direct Immunofluorescence
- 2026-07综述Diagnosis, treatment and monitoring of pediatric Behçet's disease: Systematic literature review informing the ISSAID/PRES recommendations
- 2026-07Ustekinumab for Intestinal Behçet's Disease: The First Cohort with a Novel Therapy
- 2026-07Unraveling the psychological burden of Behçet disease: the impact of anxiety and depression on health-related quality of life outcomes
- 2026-07Complex vasculitic overlap: temporal arteritis complicating suspected neuro-behçet disease with recurrent ischemic injury
- 2026-07病例报告Allogeneic haematopoietic stem cell transplantation for refractory perforating intestinal Behçet disease in a patient with aplastic anaemia: A case report
- 2026-07综述Nailfold Videocapillaroscopy in Pediatric Rheumatology: Established Roles, Emerging Applications, and Future Perspectives
- 2026-07Identification of DNA sequence variants in the Vasculo-Behcet disease patient using whole exome sequencing: a pilot study from Pakistan
- 2026-07Crohn Disease, Takayasu Arteritis, and Thrombophlebitis: Is There Underlying Behçet Disease? Genetic Clues and the Complex Role of Infliximab
- 2026-06Diabetes Mellitus Prevalence by Uveitis Etiology at a Japanese Tertiary Center
- 2026-06Artificial intelligence in rheumatology: a cross-sectional Scopus-based analysis
- 2026-06综述Abdominal manifestations of multisystem diseases: a pattern-based imaging review
- 2026-06A giant coronary aneurysm posing as a cardiac mass: The stepwise diagnosis, medical and surgical management of Behçet disease in an adolescent
- 2026-06综述Behçet's spectrum disorders: genetic and immunological insights into an emerging disease concept
- 2026-06综述开放获取Ocular TB as the only manifestation of TB: diagnostic uncertainty and treatment thresholds
- 2026-06病例报告开放获取A Case of Persistent Ataxia and Atypical Brain Lesions: From the National Multiple Sclerosis Society Case Conference Proceedings
境外已获批用于本病的药物 0L2
欧盟与美国均未检索到已获批用于本病的药物。
已获孤儿药资格、尚未获批的在研药物(1 项)
孤儿药资格只是一种监管身份——它意味着监管机构认可这是罕见病用药并给予研发激励,不代表这个药已被证明有效,也不代表将来一定能上市。绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。
- dusquetide欧盟2026-03-25Treatment of Behçet's Disease官方记录
数据来自欧洲药品管理局(EMA)的药品与孤儿药资格公开导出表,以及美国 FDA 孤儿药资格数据库。两边口径不同:欧盟一侧取的是当前状态仍为「已授权」的药品;美国一侧记录的是「曾获批准」这一事实,FDA 的公开表不追踪药物此后是否退市(例如 Relyvrio 于 2024 年撤市,表中仍记为已获批)。请以官方记录页为准。
外部标识与链接
发现这一页有错误?告诉我 · 邮件主题会自动带上本页的 ORPHA 编号
本页数据来源
- 疾病定义、同义词、基因、表型、流行病学:Orphanet(CC BY 4.0)
- 中文病名:Orphanet 中文包,冻结于 2020-06-01
- 表型中文标签:HPO 简体中文翻译(CHPO 上游成果)